Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26845500 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL31503047 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL26845492 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL26845493 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40248 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL19228951 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40148 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40286 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL9511 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40247 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| US-20250002526-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2025-01-02 | — | — | US | disclosed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023225369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | DUKE UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| WO-2023068376-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | 国立大学法人九州大学 | 2023-04-27 | — | — | WO | disclosed |
| EP-2400992-B1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH INC (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2400992-B1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH INC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-8865122-B2 | Methods and compositions for protein labelling | GENENTECH, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865122-B2 | Methods and compositions for protein labelling | GENENTECH, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130216475-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130216475-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8435488-B2 | Methods and compositions for protein labelling | GENENTECH, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435488-B2 | Methods and compositions for protein labelling | GENENTECH, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2400992-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | Genentech, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099273-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099273-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | RAB5IF, RPS27A, PSMA6 | MEN1 2279/4885KMT2A 3626/4885TSHR 2895/4885 |
| US-20250002526-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | CD274, PDCD1, PDCD1LG2 | MEN1 2631/4885KMT2A 815/4885TSHR 942/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | MEN1 3064/4885KMT2A 3544/4885TSHR 82/4885 |
| US-20130216475-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | RAB5IF, RPS27A, PSMA6 | MEN1 2279/4885KMT2A 3626/4885TSHR 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.